Medartis reported 1H21 orthopedic revenue of CHF 73.6 million (USD $83.2 million), +29.1% vs. 1H20. The company exceeded its 1H19 revenue by 14.1%.
Growth contributions came from all segments and sales regions, but Medartis called out key gains in its key priority target market of the United States. Foot and ankle sales were particularly strong in the U.S. as surgical volumes improved. The company accelerated hiring plans for sales representatives there, realigned territories and adjusted incentives. Medartis also initiated several lower extremity portfolio expansion products aimed at the U.S. market.
Given its performance through the first half, the company updated its 2021 guidance to +20% growth, or $169 million.
Revenue Data
All revenue data is provided in USD millions unless otherwise noted. Sales and growth rates are estimated on an as-reported basis.
Segment Sales
1H21
1H20
$ Chg
% Chg
Trauma
$72.5
$56.0
$16.5
29.4%
Other (CMF)
$10.6
$8.4
$2.3
27%
Total
$83.2
$64.4
$18.8
29.1%
Geographic Sales
1H21
1H20
$ Chg
% Chg
US
$14.5
$10.5
$4.0
37.6%
OUS
$68.7
$53.9
$14.8
27.5%
EMEA
$44.7
$36.2
$8.6
23.8%
APAC
$17.4
$12.2
$5.2
42.6%
ROW
$6.6
$5.5
$1.0
18.4%
Total
$83.2
$64.4
$18.8
29.1%
Earnings
Amt
% of Sales
Sales
$83.2
Cost of Sales
$13.7
16.4%
Selling
$37.1
44.6%
Administration
$13.6
16.4%
R&D
$11.9
14.3%
Other
($1.1)
(1.3%)
Net Earnings
$8.0
9.6%
Mike Evers is ORTHOWORLD’s Digital Content Strategist. He can be reached by email.
Medartis reported 1H21 orthopedic revenue of CHF 73.6 million (USD $83.2 million), +29.1% vs. 1H20. The company exceeded its 1H19 revenue by 14.1%.
Growth contributions came from all segments and sales regions, but Medartis called out key gains in its key priority target market of the United States. Foot and ankle sales were particularly...
Medartis reported 1H21 orthopedic revenue of CHF 73.6 million (USD $83.2 million), +29.1% vs. 1H20. The company exceeded its 1H19 revenue by 14.1%.
Growth contributions came from all segments and sales regions, but Medartis called out key gains in its key priority target market of the United States. Foot and ankle sales were particularly strong in the U.S. as surgical volumes improved. The company accelerated hiring plans for sales representatives there, realigned territories and adjusted incentives. Medartis also initiated several lower extremity portfolio expansion products aimed at the U.S. market.
Given its performance through the first half, the company updated its 2021 guidance to +20% growth, or $169 million.
Revenue Data
All revenue data is provided in USD millions unless otherwise noted. Sales and growth rates are estimated on an as-reported basis.
Segment Sales
1H21
1H20
$ Chg
% Chg
Trauma
$72.5
$56.0
$16.5
29.4%
Other (CMF)
$10.6
$8.4
$2.3
27%
Total
$83.2
$64.4
$18.8
29.1%
Geographic Sales
1H21
1H20
$ Chg
% Chg
US
$14.5
$10.5
$4.0
37.6%
OUS
$68.7
$53.9
$14.8
27.5%
EMEA
$44.7
$36.2
$8.6
23.8%
APAC
$17.4
$12.2
$5.2
42.6%
ROW
$6.6
$5.5
$1.0
18.4%
Total
$83.2
$64.4
$18.8
29.1%
Earnings
Amt
% of Sales
Sales
$83.2
Cost of Sales
$13.7
16.4%
Selling
$37.1
44.6%
Administration
$13.6
16.4%
R&D
$11.9
14.3%
Other
($1.1)
(1.3%)
Net Earnings
$8.0
9.6%
Mike Evers is ORTHOWORLD’s Digital Content Strategist. He can be reached by email.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.
Copy to clipboard 
